OBJECTIVE: This study compared the antitumor effect, adverse effects and survival between transcatheter arterial embolization (TAE) and transcatheter arterial infusion chemotherapy (TAI) in patients with hepatocellular carcinoma (HCC). METHODS: The study population consisted of 168 consecutive patients with advanced HCC treated with transcatheter arterial treatments using cisplatin suspended in lipiodol. Among these, 74 patients were treated with TAE, and the remaining 94 patients were treated with TAI. RESULTS: There were no significant differences in any baseline characteristics except hemoglobin, platelets, albumin, and glutamic pyruvic transaminase. Complete or partial tumor response was achieved in 54 patients (73%) in the TAE group and in 48 patients (51%) in the TAI group (p < 0.01). There were two treatment-related deaths caused by acute hepatic failure and acute renal failure in the TAE group. Nausea and deterioration of serum transaminase after TAE were significantly more severe than after TAI. Median survival time and survival rates at 5 years were 3.1 years and 25% in the TAE group, and 2.5 years and 18% in the TAI group (p = 0.37). CONCLUSION: TAE has a higher antitumor effect than TAI, but does not significantly improve the survival of patients with HCC. Copyright 2004 S. Karger AG, Basel
OBJECTIVE: This study compared the antitumor effect, adverse effects and survival between transcatheter arterial embolization (TAE) and transcatheter arterial infusion chemotherapy (TAI) in patients with hepatocellular carcinoma (HCC). METHODS: The study population consisted of 168 consecutive patients with advanced HCC treated with transcatheter arterial treatments using cisplatin suspended in lipiodol. Among these, 74 patients were treated with TAE, and the remaining 94 patients were treated with TAI. RESULTS: There were no significant differences in any baseline characteristics except hemoglobin, platelets, albumin, and glutamic pyruvic transaminase. Complete or partial tumor response was achieved in 54 patients (73%) in the TAE group and in 48 patients (51%) in the TAI group (p < 0.01). There were two treatment-related deaths caused by acute hepatic failure and acute renal failure in the TAE group. Nausea and deterioration of serum transaminase after TAE were significantly more severe than after TAI. Median survival time and survival rates at 5 years were 3.1 years and 25% in the TAE group, and 2.5 years and 18% in the TAI group (p = 0.37). CONCLUSION:TAE has a higher antitumor effect than TAI, but does not significantly improve the survival of patients with HCC. Copyright 2004 S. Karger AG, Basel
Authors: Brian Jin; Dingxin Wang; Robert J Lewandowski; Ahsun Riaz; Robert K Ryu; Kent T Sato; Andrew C Larson; Riad Salem; Reed A Omary Journal: AJR Am J Roentgenol Date: 2011-04 Impact factor: 3.959
Authors: Brian Jin; Dingxin Wang; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Andrew C Larson; Riad Salem; Reed A Omary Journal: AJR Am J Roentgenol Date: 2011-11 Impact factor: 3.959